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Central venous access port devices (CVAPD) are necessary for delivery of prolonged infusional chemotherapy or in patients with
poor peripheral venous access. Previous studies of Hickman catheters report complication rates in about 45% of patients. Our aim
was to assess the early and late complication rate, and duration that the CVAPD remained functional, following insertion by
interventional radiologists in patients with solid tumours. A prospective study was undertaken in 110 consecutive patients who had
insertion of 111 subclavian CVAPD. The median age of patients was 57 years (range 17–83), 64 were females; 68 patients (61%) had
gastrointestinal tumours and 25 (23%) had breast cancer. CVAPD were successfully implanted in all but one patient. There were four
(4%) immediate major complications: thrombosis 2 and pneumothorax 2. Nine patients (8%) had bruising or pain. Four devices (4%)
became infected. In total, 100 CVAPD (90%) were either removed as planned at the end of treatment (n¼23) after a median 203
days, or remained in situ for a median of 237 days (7–1133). Premature removal occurred in eight patients due to infection (n¼4),
thrombosis (n¼3) or faulty device (n¼1). Four patients were lost to follow-up. Radiological insertion of CVAPD is safe and
convenient with low rates of complications.
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Central venous access devices have been used to deliver
chemotherapy since the 1970s. In patients with solid cancers they
are used mainly to overcome poor peripheral venous access or for
prolonged infusional chemotherapy.
There are three types of central venous devices: external central
catheters (e.g. Hickman’s catheters), peripherally inserted central
catheters (PICC) and subcutaneously implanted venous access
devices. External catheters are desirable when multiple lumens are
necessary for the concurrent administration of different solutions,
but they are associated with high rates of catheter-related infection
and thrombosis; reported complication rates are as high as 45%
(Eastridge and Lefor, 1995; Biffi et al, 1997, 1998). Patients with
external catheters also require more frequent catheter irrigation
and dressing changes than those with fully implanted venous
access devices. While the initial cost of CVAPD is high (Biffi et al,
1998), a case–control study comparing durability and cost of
CVAPD and external catheters demonstrated long-term economic
benefit for CVAPD for use beyond 6 months due to lower ongoing
maintenance costs (McCready et al, 1991). Peripheral external
catheters are relatively inexpensive and can be inserted by trained
nurses at the bedside, however, they are only a short-term option,
with similar complications to Hickman catheters.
Implanted venous access devices can be inserted either
peripherally near the antecubital fossa (Pasports) or centrally into
the subclavian or jugular vein (CVAPD). Instead of an external
catheter the tunneled catheter terminates into a subcutaneously
implanted reservoir. This makes them suitable for active patients
and more acceptable cosmetically (Lokich et al, 1985; Biffi et al,
1998; Lyon et al, 1999). Peripheral ports have a lower risk of
infection than CVAPD (Salem et al, 1993; Damascelli et al, 1997)
and their insertion involves a minimal risk of pneumothorax and
haemothorax. However, they have a shorter useful lifetime than
CVAPD (Smith et al, 1998) and there is an increased risk of venous
sclerosis following the use of cytotoxic agents (Slater et al, 1985),
which makes them unsuitable for cancer patients receiving longer-
term chemotherapy.
Traditionally, CVAPD have been implanted by surgeons or
anaesthetists in an operating room. More recently, interventional
radiologists have been inserting them using local anaesthesia and
fluoroscopic guidance. This method is more efficient, and recent
studies including our own, have demonstrated a favourable success
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lrate and low complication rate following radiological insertion of
portacaths (Morris et al, 1992; Simpson et al, 1997; Lorch et al,
2001).
The data presented here represents the initial experience with
110 cancer patients undergoing outpatient insertion of CVAPD by
radiologists, for the administration of chemotherapy, at two
Sydney teaching hospitals. The present study differs from
published studies of long-term indwelling catheters (reviewed
below) in that it is prospective and so avoids the numerous
attendant problems associated with retrospective collection of
data. Our study population is relatively homogenous consisting of
patients with solid tumours, who require long-term indwelling
venous access for chemotherapy, in contrast to other studies which
include patients with solid and haematological malignancies, and/
or those with HIV or chronic infections requiring long-term
antibiotics. Oncology patients are at higher risk than the general
medical population for complications such as thrombosis; but at
lower risk than acute leukaemic patients for sepsis. In addition,
our study evaluates only CVAPD inserted as an outpatient
procedure by interventional radiologists. A number of the other
studies include a mixture of different types of venous access
devices, so that comparison of complication rates is difficult.
Finally, our study is not only prospective but also has a long
follow-up (minimum of 18 months).
MATERIALS AND METHODS
Patient selection
All patients had histologically confirmed malignancy other than
leukaemia and required the insertion of a CVAPD for the
administration of chemotherapy. Approval for the study was
obtained from the Institutional Review Board, and all patients gave
informed consent.
The CVAPD were inserted with fluoroscopic guidance by one of
three interventional radiologists as an outpatient procedure. All
CVAPDs were inserted into the subclavian vein. When possible,
the right subclavian vein was used for technical ease of right-
handed operators. In all, 54 patients had insertion of a BardPort
s
with an 8F Groshong
s catheter (Bard Inc., Salt Lake City, USA),
while 57 had a Vital-Port
s with a 6.5F silicone catheter (Cook
Vascular Corporation, Pennsylvania, USA). A full blood count and
coagulation studies were performed prior to the procedure and
patients and their carers received education prior to and following
CVAPD insertion.
At the commencement of the procedure, patients received
midazolam 2mg i.v. and pethidine 25–100mg i.v., with further
increments of midazolam being administered as required during
the procedure. Local anaesthetic was injected into the skin
surrounding the planned puncture site after preparation of the
skin. All patients received cephalothin 1g i.v. as prophylaxis
against infection or 300mg oral clindamycin if there was a history
of penicillin/cephalosporin allergy. A mixture of 50ml of contrast
(Ultravist 370) and saline 30ml was injected peripherally to
identify the site of subclavian vein puncture. A postprocedural
chest X-ray (CXR) was performed to document final catheter
position and to exclude pneumothorax. Warfarin 1mg orally daily
was commenced after CVAPD insertion in order to prevent
catheter thrombosis (Bern et al, 1990).
The patients and CVAPD were assessed by Oncology nursing
staff immediately postinsertion and most CVAPDs were accessed
immediately. Follow-up assessment occurred at intervals of 4
weeks or less. The patient was questioned about symptoms
suggestive of infection and problems with catheter function, and
the insertion site was examined for evidence of infection, bruising
or other complication. Patients were followed until the device
was removed or the patient died. Complications were classified
as acute if they occurred within 1 week of insertion of the device,
and delayed if they occurred after this. CVAPD infection was
defined as a positive blood culture with no other obvious source
of infection.
Statistical methods
Descriptive statistics were used to summarise demographic and
CVAPD characteristics. Analysis involved the use of simple
summary statistics. Actuarial curves describing retention of
functional CVAPD was estimated using the Kaplan–Meier method.
A successful CVAPD was one that was still in situ and working, at
the time of death of a patient or removal of a functional port, as
planned upon completion of chemotherapy treatment.
RESULTS
In all, 111 CVAPD were inserted in 110 patients from June 1998 to
July 2001. There were 46 males and 64 females ranging from 17–83
years old with a median age of 57 years. The predominant
malignancies were gastrointestinal (61%) and breast cancer (23%).
Overall, 99 CVAPD were inserted on the right side and 12 on
the left.
Complications associated with the CVAPD are summarised
in Table 1. CVAPD were successfully implanted in all but one
patient (1%) where there was device failure with the catheter
disengaging from the port, necessitating immediate removal in
the operating room. Most CVAPD (n¼108, 97%) were inserted
with a single pass. Acutely there were four major complications
(4%). Two patients (2%) developed thromboses, which were
successfully treated with anticoagulation and did not require port
removal, and two (2%) patients developed a pneumothorax
requiring insertion of an intercostal catheter. Totally, 10 patients
(9%) had minor acute complications: five (4.5%) developed a
haematoma at the site of the port insertion, and five (4.5%)
described moderate–severe pain at the port site, requiring
analgesia.
Delayed complications requiring removal of the port occurred in
seven patients (6.3%). Four patients (4%) developed infections
necessitating removal of their CVAPD: three secondary to
Staphylococcus aureus infection (days 12, 21 and 282) and one
Pseudomonas aeruginosa requiring port removal at day 611. Two
(2%) additional patients had S. aureus infection successfully
treated with antibiotics. Two patients (2%) developed delayed
thrombosis requiring removal of the port (days 61 and 127); one of
them had prior thrombosis treated with anticoagulants. The other
patient had port removal and a second port inserted immediately.
Table 1 Summary of CVAPD complications
%
Acute complications
Major
Inability to insert 1
Thrombosis 2
Pneumothorax requiring ICC
a 2
Minor
Haematoma 4.5
Pain at port site 4.5
Delayed complications
Infection - port removal 4
Infection - antibiotics 2
Thrombosis 3
aICC¼ intercostal catheter.
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lIn total, 100 (90%) CVAPD served their intended purpose for as
long as they were required. In all, 26 (23%) functional CVAPD
were removed as planned upon completion of chemotherapy, with
a median duration of insertion of 7 months (range 2–19 months).
Overall, 63 (60%) patients died with a functional CVAPD in situ at
a median of 7 months (range 0–33 months), and 11 (10%) patients
were alive with a functional CVAPD in situ at the conclusion of the
study (median duration of insertion¼30 months; range 25–37).
Thus, 74 (67%) CVAPD remained in situ for a median of 8 months
(range 0–37 months). Four (3.6%) patients were lost to follow-up.
At 2 years there is a one in six chance that a CVAPD will need to be
removed (see Figure 1).
DISCUSSION
CVAPD are used increasingly in the treatment of cancer patients
for administration of continuous infusional chemotherapy; and to
avoid frequent venipunctures, which become increasingly difficult
after multiple courses of chemotherapy. Patients prefer the
cosmetic result of a fully implanted venous device compared to a
central venous device with external lines (Lyon et al, 1999). The
implanted device is particularly desirable for patients with active
lifestyles and they require less maintenance than external tunneled
catheters. A major advantage of having the CVAPD inserted by an
interventional radiologist is that it is an outpatient procedure
without need for operating room time.
Table 2 summarises the complication rates of the larger
published studies of CVAPD inserted by radiologists and
surgeons, as well as studies of external catheters and peripheral
ports. There is little standardisation of the definitions used
for complications. For example, some studies restrict the defini-
tion of infection to those patients with proven positive cultures,
while others include patients with fever and/or clinical evidence
of infection despite negative cultures. A number of the studies
only included a complication if it led to major sequelae such
as the venous access device being removed. An attempt has
been made to address this problem with the development of
Reporting Standards for Central Venous Access (Silberzweig
et al, 2000).
In our study, 4% of patients developed immediate complications
of thrombosis or pneumothorax. Our rates are consistent with
other published studies of CVAPD inserted by interventional
radiologists. The range of complication rates for CVAPD inserted
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Figure 1 Actuarial curves describing retention of functional CVAPD.
Solid line¼survival of functional CVAPD. Dotted line¼95% confidence
interval.
Table 2 Summary of venous access device studies
Author Year
No of
devices
Inserted
by
Type of
device
Infection
(%)
Thrombosis
(%)
Pneumothorax
(%)
Device
malfunction
(%)
Removal for
Complication
(%)
Mean
catheter
life
(months)
Months of
service
Vardy, 2004 111 Radiology CVAPD 4 2 2 1 7 7 1222
Lorch et al, 2001 125 Radiology CVAPD 2.4 0 1.6 2.4 4.8 3 364
de Gregorio
et al,
1996 288 Radiology CVAPD 4.1 4.5 0.7 1.4 18 10 2984
Biffi et al, 1998 333 Surgery CVAPD 2.7 1.5 3.4 2.7 3.6 8 2605
Schwarz et al, 1997 680 Surgery CVAPD 8.8 3 0 1.7 14.1 39 N/A
Kock et al, 1998 1500 Surgery CVAPD 3.2 2.5 0.3 2.8 11.9 9 14013
Eastridge
and Lefor,
1995 113 Surgery CVAPD 5 6 1.2 total 6% total 13.2 N/A N/A
209 Surgery Catheters 13 10 32 N/A N/A
Damascelli et al, 1997 30 Radiology CVAPD 8.3 0 Total 3% 2.8 5.5 8 809
111 Radiology Catheters 6.3 1.8 1.8 10.8
Groeger et al, 1993 788 Surgery Catheters 43 N/A N/A N/A N/A N/A 5451
680 Surgery CVAPD 8 N/A N/A N/A N/A N/A 9140
Gertner et al, 2000 278 N/A Catheters 12.5 1.5 N/A 5.2 N/A 5 N/A
110 N/A CVAPD 4.6 1.1 N/A 0 N/A 7 N/A
Tolar and Gould, 1996 324 Surgery Catheters 19.4 16.6 N/A 33.4 N/A 6 1969
Broadwater et al, 1990 763 Surgery Catheters 4 3 2 N/A 25 6 N/A
Nightingale et al, 1997 949 Surgery Catheters 10.6 4.4 1.8 2.2 18.6 4 3273
Smith et al, 1998 283 Surgery Catheters
and CVAPD
11.7 0.7 1.4 3.9 N/A 7 1624
555 Nurses PICCs 8.1 2.5 0 11.7 N/A 23 389
Walshe et al, 2002 351 Nurses/Rad PICCS 7.4 3.4 0 6 32.8 1 347
Marcy et al, 2001 652 Radiology Peripheral ports 0.9 1.2 0 1.8 4 5 N/A
Lyon et al, 1999 195 Radiology Peripheral ports 5.1 4.6 0 5.1 9.7 6 1105
Hills et al, 1997 100 Radiology Peripheral ports 7 0 0 0 6.2 8 784
N/A¼not available.
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lby surgeons is generally higher (Table 2). Thus, the method of
insertion may affect the outcome.
A number of the studies attempted to compare CVAPD with
either Groshong catheters or Hickman catheters and consistently
found a higher rate of complications in the central external
catheters (Mueller et al, 1992; Gleeson et al, 1993; Groeger et al,
1993; Eastridge and Lefor, 1995) (Table 2).
Complication rates of peripheral catheter (PICCS) are shown in
Table 2. Walshe’s study report 6.6% of PICCS removed for
phlebitis. Complication rates of peripheral passports are similar to
CVAPD with the exception of lower rates for pneumothorax
(Table 2).
Direct comparisons between the studies summarised in
Table 2 are difficult, because they were applied to different
patient populations with different disease states. There is an
increased rate of thrombosis in cancer patients and complica-
tion rates in cancer patients are likely to depend on the type
of malignancy and its attendant treatment. Patients with
cancer having lines inserted for administration of chemo-
therapy will commonly become neutropenic leading to a higher
risk of line infection than in general medical patients (Walshe
et al, 2002).
Despite the above difficulties, the consensus of the studies
reviewed in Table 2 supports the use of CVAPD over external
catheters for patients. The low complication rate associated with
CVAPD ensures that a large majority of patients is able to complete
their chemotherapy without delays.
Our experience indicates that insertion of CVAPD by interven-
tional radiologists has resulted in less time delays for patients
commencing treatment than we used to experience with surgical
insertion. This is due primarily to not having to wait for operating
room time.
Our prospective study of solid tumour patients has found
radiological insertion of CVAPD to be safe and to compare
favourably with surgical insertion. Insertion by interventional
radiologists has been more convenient and is favoured by both
medical oncologists and patients. With the increased use of
continuous infusional chemotherapy regimes there is likely to be a
substantial increase in the requirement for CVAPD.
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